The coordinated buying by three large passive managers suggests growing confidence in CCCC’s pipeline or valuation, potentially ahead of clinical catalysts. Traders should monitor for upcoming trial data or partnerships as potential near-term triggers.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 2 $3.17entry
- T+1 · 9mo ago −6.94%α −6.03% · $2.95
- T+5 · 8mo ago +13.25%α +14.46% · $3.59
- T+20 · 8mo ago −25.87%α −17.93% · $2.35
- T+60 · 6mo ago +10.09%α +0.77% · $3.49
How similar events traded
Executive Summary
Three major institutional investors, Morgan Stanley, Wells Fargo, and UBS, increased their positions in C4 Therapeutics (CCCC) during Q4 2024, with UBS doubling its stake. The aggregate buying activity totaled $1.4M in net new investment, signaling growing institutional interest in the small-cap biotech firm.
Key Financial Metrics
Institutional Positions
Net institutional flow: $1.4M
▲ Buyers (3)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | ADD | +65.1% | $13.8M | $563.0K |
| UBS | DOUBLED | +126.8% | $2.7M | $824.0K |
| Wells Fargo | ADD | +34.9% | $131.0K | -$22.7K |
Key Facts
- Morgan Stanley increased its stake by 65.1%, adding 1.51M shares with a value increase of $563K to a total of $13.8M.
- UBS doubled its position, increasing shares by 126.8% (423.8K shares added), growing its investment value by $824K to $2.7M.
- Wells Fargo added 9.4K shares (+34.9%), though the value of its position decreased slightly by $22,725 to $131K, likely due to share price movement during the period.
- No institutional selling was observed, all three tracked institutions were net buyers.
Financial Impact
Institutions added $1.4M in net new positions during Q4 2024, with total current holdings now at $16.7M.
Risk Factors
- All buyers are classified as mega-passive institutions, which may indicate index-driven or model-based buying rather than high-conviction active bets.
- CCCC has a small market cap ($401M), making it vulnerable to volatility if sentiment shifts or institutions rebalance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-CCCC-2024-Q4 |
Track record
19 reports on CCCC
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +46.29% at T+60 after the Apr 9, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.71 settles Nov 23
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $2.76 settles Nov 20
- Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $3.10 to $2.76 ▼ −10.97% −13.56% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $2.95 to $2.77 ▼ −6.10% −9.39% vs SPY
- Sep 25, 20267w ago 8-K Neutral 4/10 Entry $2.98 to $2.95 ▼ −1.01% −0.79% vs SPY
- Sep 25, 20267w ago Press Release Neutral 4/10 Entry $2.98 to $2.95 ▼ −1.01% −0.79% vs SPY
- Aug 14, 202613w ago 144 Neutral 3/10 Entry $4.27 to $4.10 ▼ −3.87% −2.68% vs SPY
- Aug 14, 202613w ago Institutional Cluster Bullish 6/10 Entry $4.27 to $4.10 ▼ −3.87% −2.68% vs SPY
- Aug 11, 202613w ago 8-K Neutral 5/10 Entry $3.87 to $4.18 ▲ +8.01% +8.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers